Results 71 to 80 of about 20,740 (205)

Activation of tyrosinase kinase and microfilament-binding functions of c-abl by bcr sequences in bcr/abl fusion proteins. [PDF]

Molecular and Cellular Biology, 1991
Chronic myelogenous leukemia and one type of acute lymphoblastic leukemia are characterized by a 9;22 chronosome translocation in which 5' sequences of the bcr gene become fused to the c-abl proto-oncogene. The resulting chimeric genes encode bcr/abl fusion proteins which have deregulated tyrosine kinase activity and appear to play an important role in
J R, McWhirter, J Y, Wang
openaire   +2 more sources

Self-assembled Human Serum Protein-based Core-shell Nanoparticles to inhibit key oncogenic signalling in Drug-Resistant Leukemia

Precision Nanomedicine
Simultaneous inhibition of multiple oncogenic signaling pathways is crucial for managing refractory cancers. This study introduces two unique core-shell nanoparticle (CS-NP) systems crafted from natural proteins that simultaneously target two crucial ...
Archana Payickattu Retnakumary, Lekshmi G Kumar, Neeraj Sidharthan, Pavithran Keechilat, Giridharan L. Malarvizhi, Prasanna L Hanumanthu, Madhavan V Thampi, Deepthy Menon, Krishnakumar Menon, Shantikumar V Nair, Manzoor Koyakutty   +10 more
doaj   +1 more source

Computational and mechanistic studies on the effect of galactoxyloglucan: Imatinib nanoconjugate in imatinib resistant K562 cells

Tumor Biology, 2017
Imatinib mesylate, a BCR/ABL fusion protein inhibitor, is the first-line treatment against chronic myelogenous leukemia. In spite of its advantageous viewpoints, imatinib still has genuine impediments like undesirable side effects and tumor resistance ...
Alphy Rose James, BS Unnikrishnan, R Priya, Manu M Joseph, TK Manojkumar, K Raveendran Pillai, R Shiji, GU Preethi, P Kusumakumary, TT Sreelekha   +9 more
doaj   +1 more source

Neuropsychiatric Symptoms Mimicking Dementia in a Patient Treated With Imatinib

Annals of Clinical and Translational Neurology, Volume 13, Issue 4, Page 840-844, April 2026.
ABSTRACT Tyrosine kinase inhibitors are the cornerstone of chronic myeloid leukemia treatment. Newer agents have more potency and a broader spectrum of action, but also a higher potential for neuropsychiatric side effects. We present a case of a patient on imatinib who developed progressive cognitive, mood, and behavioral alterations.
Ashley Jones, Samuele Bonomi, Keith E. Stockerl‐Goldstein, Randall J. Bateman   +3 more
wiley   +1 more source

Perturbation of Methionine/S-adenosylmethionine Metabolism as a Novel Vulnerability in MLL Rearranged Leukemia

Cells, 2019
Leukemias bearing mixed lineage leukemia (MLL) rearrangement (MLL-R) resulting in expression of oncogenic MLL fusion proteins (MLL-FPs) represent an especially aggressive disease subtype with the worst overall prognoses and chemotherapeutic response. MLL-
Aditya Barve, Alexis Vega, Parag P. Shah, Smita Ghare, Lavona Casson, Mark Wunderlich, Leah J. Siskind, Levi J. Beverly   +7 more
doaj   +1 more source

Dual gene activation and knockout screen reveals directional dependencies in genetic networks. [PDF]

, 2018
Understanding the direction of information flow is essential for characterizing how genetic networks affect phenotypes. However, methods to find genetic interactions largely fail to reveal directional dependencies. We combine two orthogonal Cas9 proteins
Biton, Anne, Blau, James A, Boettcher, Michael, Fu, Haian, Kampmann, Martin, Markegard, Evan, McCormick, Frank, McManus, Michael T, Mo, Xiulei, Tian, Ruilin, Wagner, Ryan T, Wu, David, Zaitlen, Noah   +12 more
core   +2 more sources

Super‐Enhancer‐Driven SOX4/SMAD3 Mediate Membrane Remodeling by Regulating Phospholipid Metabolism to Accelerate Leukemia Progression

Advanced Science, Volume 13, Issue 24, 27 April 2026.
Chronic myeloid leukemia blast phase (CML‐BP) poses a severe therapeutic challenge. This study reveals that the super‐enhancer‐driven transcription factors SOX4 and SMAD3 form a cooperative axis critical for disease progression. They co‐activate the oncogenic kinase AXL and promote phospholipid remodeling via LPCAT1 to facilitate its signaling ...
Enzhe Lou, Peilong Lai, Guanjie Peng, Bo Lu, Lizhen Jiang, Xinyue Li, Jinghong Chen, Ladi Mo, Qiong Mao, Haichuan Zhang, Jinxin Fang, Yi Meng, Aochu Liu, Yingyin Gao, Andong Huang, Wenhui Lin, Shiwen Hu, Zerong Guan, Xiaolan Ye, Zhenguo Liu, Liling Jiang, Yueyuan Zheng, Xianping Shi   +22 more
wiley   +1 more source

The tyrosine phosphatase TC48 interacts with and inactivates the oncogenic fusion protein BCR-Abl but not cellular Abl

Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2013
The chimeric oncoprotein BCR-Abl exhibits deregulated protein tyrosine kinase activity and is responsible for the pathogenesis of certain human leukemias, such as chronic myelogenous leukemia. The activities of cellular Abl (c-Abl) and BCR-Abl are stringently regulated and the cellular mechanisms involved in their inactivation are poorly understood ...
Mitra, Aninda, Sasikumar, Kotagiri, Parthasaradhi, B.V.V., Radha, Vegesna   +3 more
openaire   +2 more sources

Detection of a rare BCR–ABL tyrosine kinase fusion protein in H929 multiple myeloma cells using immunoprecipitation (IP)-tandem mass spectrometry (MS/MS) [PDF]

Proceedings of the National Academy of Sciences, 2012
Hypothesis directed proteomics offers higher throughput over global analyses. We show that immunoprecipitation (IP)–tandem mass spectrometry (LC-MS/MS) in H929 multiple myeloma (MM) cancer cells led to the discovery of a rare and unexpected BCR–ABL fusion, informing a therapeutic intervention using imatinib (Gleevec). BCR–ABL is the driving mutation in
Susanne B, Breitkopf, Min, Yuan, German A, Pihan, John M, Asara   +3 more
openaire   +2 more sources

Eosinofilia reacional, leucemia eosinofílica crônica e síndrome hipereosinofílica idiopática Reactive eosinophilia, chronic eosinophilic leukemia and idiopathic hypereosinophilic syndrome

Revista Brasileira de Hematologia e Hemoterapia, 2010
A eosinofilia é freqüente na prática clínica, principalmente quando os valores estão entre 500 e 1000 eosinófilos/uL e indica a presença de doença parasitária, alérgica ou reação a medicamentos.
Maria de Lourdes Lopes Ferrari Chauffaille
doaj   +1 more source